NCT01648205View on ClinicalTrials.gov

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 20, 2018

Study Completion Date

July 20, 2018

Conditions
Long QT Syndrome
Interventions
DRUG

Placebo

Matching Placebo will be given for first month.

DRUG

Ranolazine

Patients will receive ranolazine 1000mg bid for subsequent 5 months.

Trial Locations (1)

14642

University of Rochester, Rochester

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Rochester

OTHER